RYAN FILIATREAU: Open Payments
NPI 1922296664 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$230 in 12 payments from 9 companies in 2025. Trend: 2023 $363 · 2024 $386 · 2025 $230
Food & beverage: $215Education: $15
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $55 |
| Janssen Biotech, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Amgen Inc. | 1 | $21 |
| UCB, Inc. | 1 | $16 |
| Galderma Laboratories, L.P. | 1 | $16 |
| ABBVIE INC. | 1 | $16 |
| PFIZER INC. | 1 | $15 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
Products named: Rhapsido, TREMFYA, TALTZ, OTEZLA, Bimzelx, NEMLUVIO, SKYRIZI, CIBINQO.
Industry payments across KY — which companies pay providers there.
